Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011981165> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W3011981165 abstract "Article Figures and data Abstract eLife digest Introduction Results Discussion Materials and methods Data availability References Decision letter Author response Article and author information Metrics Abstract Bats host virulent zoonotic viruses without experiencing disease. A mechanistic understanding of the impact of bats’ virus hosting capacities, including uniquely constitutive immune pathways, on cellular-scale viral dynamics is needed to elucidate zoonotic emergence. We carried out virus infectivity assays on bat cell lines expressing induced and constitutive immune phenotypes, then developed a theoretical model of our in vitro system, which we fit to empirical data. Best fit models recapitulated expected immune phenotypes for representative cell lines, supporting robust antiviral defenses in bat cells that correlated with higher estimates for within-host viral propagation rates. In general, heightened immune responses limit pathogen-induced cellular morbidity, which can facilitate the establishment of rapidly-propagating persistent infections within-host. Rapidly-transmitting viruses that have evolved with bat immune systems will likely cause enhanced virulence following emergence into secondary hosts with immune systems that diverge from those unique to bats. eLife digest Bats can carry viruses that are deadly to other mammals without themselves showing serious symptoms. In fact, bats are natural reservoirs for viruses that have some of the highest fatality rates of any viruses that people acquire from wild animals – including rabies, Ebola and the SARS coronavirus. Bats have a suite of antiviral defenses that keep the amount of virus in check. For example, some bats have an antiviral immune response called the interferon pathway perpetually switched on. In most other mammals, having such a hyper-vigilant immune response would cause harmful inflammation. Bats, however, have adapted anti-inflammatory traits that protect them from such harm, include the loss of certain genes that normally promote inflammation. However, no one has previously explored how these unique antiviral defenses of bats impact the viruses themselves. Now, Brook et al. have studied this exact question using bat cells grown in the laboratory. The experiments made use of cells from one bat species – the black flying fox – in which the interferon pathway is always on, and another – the Egyptian fruit bat – in which this pathway is only activated during an infection. The bat cells were infected with three different viruses, and then Brook et al. observed how the interferon pathway helped keep the infections in check, before creating a computer model of this response. The experiments and model helped reveal that the bats’ defenses may have a potential downside for other animals, including humans. In both bat species, the strongest antiviral responses were countered by the virus spreading more quickly from cell to cell. This suggests that bat immune defenses may drive the evolution of faster transmitting viruses, and while bats are well protected from the harmful effects of their own prolific viruses, other creatures like humans are not. The findings may help to explain why bats are often the source for viruses that are deadly in humans. Learning more about bats' antiviral defenses and how they drive virus evolution may help scientists develop better ways to predict, prevent or limit the spread of viruses from bats to humans. More studies are needed in bats to help these efforts. In the meantime, the experiments highlight the importance of warning people to avoid direct contact with wild bats. Introduction Bats have received much attention in recent years for their role as reservoir hosts for emerging viral zoonoses, including rabies and related lyssaviruses, Hendra and Nipah henipaviruses, Ebola and Marburg filoviruses, and SARS coronavirus (Calisher et al., 2006; Wang and Anderson, 2019). In most non-Chiropteran mammals, henipaviruses, filoviruses, and coronaviruses induce substantial morbidity and mortality, display short durations of infection, and elicit robust, long-term immunity in hosts surviving infection (Nicholls et al., 2003; Hooper et al., 2001; Mahanty and Bray, 2004). Bats, by contrast, demonstrate no obvious disease symptoms upon infection with pathogens that are highly virulent in non-volant mammals (Schountz et al., 2017) but may, instead, support viruses as long-term persistent infections, rather than transient, immunizing pathologies (Plowright et al., 2016). Recent research advances are beginning to shed light on the molecular mechanisms by which bats avoid pathology from these otherwise virulent pathogens (Brook and Dobson, 2015). Bats leverage a suite of species-specific mechanisms to limit viral load, which include host receptor sequence incompatibilities for some bat-virus combinations (Ng et al., 2015; Takadate et al., 2020) and constitutive expression of the antiviral cytokine, IFN-α, for others (Zhou et al., 2016). Typically, the presence of viral RNA or DNA in the cytoplasm of mammalian cells will induce secretion of type I interferon proteins (IFN-α and IFN-β), which promote expression and translation of interferon-stimulated genes (ISGs) in neighboring cells and render them effectively antiviral (Stetson and Medzhitov, 2006). In some bat cells, the transcriptomic blueprints for this IFN response are expressed constitutively, even in the absence of stimulation by viral RNA or DNA (Zhou et al., 2016). In non-flying mammals, constitutive IFN expression would likely elicit widespread inflammation and concomitant immunopathology upon viral infection, but bats support unique adaptations to combat inflammation (Zhang et al., 2013; Ahn et al., 2019; Xie et al., 2018; Pavlovich et al., 2018) that may have evolved to mitigate metabolic damage induced during flight (Kacprzyk et al., 2017). The extent to which constitutive IFN-α expression signifies constitutive antiviral defense in the form of functional IFN-α protein remains unresolved. In bat cells constitutively expressing IFN-α, some protein-stimulated, downstream ISGs appear to be also constitutively expressed, but additional ISG induction is nonetheless possible following viral challenge and stimulation of IFN-β (Zhou et al., 2016; Xie et al., 2018). Despite recent advances in molecular understanding of bat viral tolerance, the consequences of this unique bat immunity on within-host virus dynamics—and its implications for understanding zoonotic emergence—have yet to be elucidated. The field of ‘virus dynamics’ was first developed to describe the mechanistic underpinnings of long-term patterns of steady-state viral load exhibited by patients in chronic phase infections with HIV, who appeared to produce and clear virus at equivalent rates (Nowak and May, 2000; Ho et al., 1995). Models of simple target cell depletion, in which viral load is dictated by a bottom-up resource supply of infection-susceptible host cells, were first developed for HIV (Perelson, 2002) but have since been applied to other chronic infections, including hepatitis-C virus (Neumann et al., 1998), hepatitis-B virus (Nowak et al., 1996) and cytomegalovirus (Emery et al., 1999). Recent work has adopted similar techniques to model the within-host dynamics of acute infections, such as influenza A and measles, inspiring debate over the extent to which explicit modeling of top-down immune control can improve inference beyond the basic resource limitation assumptions of the target cell model (Baccam et al., 2006; Pawelek et al., 2012; Saenz et al., 2010; Morris et al., 2018). To investigate the impact of unique bat immune processes on in vitro viral kinetics, we first undertook a series of virus infection experiments on bat cell lines expressing divergent interferon phenotypes, then developed a theoretical model elucidating the dynamics of within-host viral spread. We evaluated our theoretical model analytically independent of the data, then fit the model to data recovered from in vitro experimental trials in order to estimate rates of within-host virus transmission and cellular progression to antiviral status under diverse assumptions of absent, induced, and constitutive immunity. Finally, we confirmed our findings in spatially-explicit stochastic simulations of fitted time series from our mean field model. We hypothesized that top-down immune processes would overrule classical resource-limitation in bat cell lines described as constitutively antiviral in the literature, offering a testable prediction for models fit to empirical data. We further predicted that the most robust antiviral responses would be associated with the most rapid within-host virus propagation rates but also protect cells against virus-induced mortality to support the longest enduring infections in tissue culture. Results Virus infection experiments in antiviral bat cell cultures yield reduced cell mortality and elongated epidemics We first explored the influence of innate immune phenotype on within-host viral propagation in a series of infection experiments in cell culture. We conducted plaque assays on six-well plate monolayers of three immortalized mammalian kidney cell lines: [1] Vero (African green monkey) cells, which are IFN-defective and thus limited in antiviral capacity (Desmyter et al., 1968); [2] RoNi/7.1 (Rousettus aegyptiacus) cells which demonstrate idiosyncratic induced interferon responses upon viral challenge (Kuzmin et al., 2017; Arnold et al., 2018; Biesold et al., 2011; Pavlovich et al., 2018); and [3] PaKiT01 (Pteropus alecto) cells which constitutively express IFN-α (Zhou et al., 2016; Crameri et al., 2009). To intensify cell line-specific differences in constitutive immunity, we carried out infectivity assays with GFP-tagged, replication-competent vesicular stomatitis Indiana viruses: rVSV-G, rVSV-EBOV, and rVSV-MARV, which have been previously described (Miller et al., 2012; Wong et al., 2010). Two of these viruses, rVSV-EBOV and rVSV-MARV, are recombinants for which cell entry is mediated by the glycoprotein of the bat-evolved filoviruses, Ebola (EBOV) and Marburg (MARV), thus allowing us to modulate the extent of structural, as well as immunological, antiviral defense at play in each infection. Previous work in this lab has demonstrated incompatibilities in the NPC1 filovirus receptor which render PaKiT01 cells refractory to infection with rVSV-MARV (Ng and Chandrab, 2018, Unpublished results), making them structurally antiviral, over and above their constitutive expression of IFN-α. All three cell lines were challenged with all three viruses at two multiplicities of infection (MOI): 0.001 and 0.0001. Between 18 and 39 trials were run at each cell-virus-MOI combination, excepting rVSV-MARV infections on PaKiT01 cells at MOI = 0.001, for which only eight trials were run (see Materials and methods; Figure 1—figure supplements 1–3, Supplementary file 1). Because plaque assays restrict viral transmission neighbor-to-neighbor in two-dimensional cellular space (Howat et al., 2006), we were able to track the spread of GFP-expressing virus-infected cells across tissue monolayers via inverted fluorescence microscopy. For each infection trial, we monitored and re-imaged plates for up to 200 hr of observations or until total monolayer destruction, processed resulting images, and generated a time series of the proportion of infectious-cell occupied plate space across the duration of each trial (see Materials and methods). We used generalized additive models to infer the time course of all cell culture replicates and construct the multi-trial dataset to which we eventually fit our mechanistic transmission model for each cell line-virus-specific combination (Figure 1; Figure 1—figure supplements 1–5). Figure 1 with 7 supplements see all Download asset Open asset Fitted time series of infectious cell proportions from mean field model for rVSV-G, rVSV-EBOV, and rVSV-MARV infections (columns) on Vero, RoNi/7.1, and PaKiT01 cell lines (rows) at MOI = 0.001. Results are shown for the best fit immune absent model on Vero cells, induced immunity model on RoNi/7.1 cells, and constitutive (for rVSV-VSVG and rVSV-EBOV) and induced (for rVSV-MARV) immunity models on PaKiT01 cells. Raw data across all trials are shown as open circles (statistical smoothers from each trial used for fitting are available in Figure 1—figure supplements 2–3). Model output is shown as a solid crimson line (95% confidence intervals by standard error = red shading). Panel background corresponds to empirical outcome of the average stochastic cell culture trial (persistent infection = white; virus-induced epidemic extinction = gray; immune-mediated epidemic extinction = black). Parameter values are listed in Table 1 and Supplementary file 4. Results for absent/induced/constitutive fitted models across all cell lines are shown in Figure 1—figure supplement 4 (MOI = 0.001) and Figure 1—figure supplement 5 (MOI = 0.0001). All three recombinant vesicular stomatitis viruses (rVSV-G, rVSV-EBOV, and rVSV-MARV) infected Vero, RoNi/7.1, and PaKiT01 tissue cultures at both focal MOIs. Post-invasion, virus spread rapidly across most cell monolayers, resulting in virus-induced epidemic extinction. Epidemics were less severe in bat cell cultures, especially when infected with the recombinant filoviruses, rVSV-EBOV and rVSV-MARV. Monolayer destruction was avoided in the case of rVSV-EBOV and rVSV-MARV infections on PaKiT01 cells: in the former, persistent viral infection was maintained throughout the 200 hr duration of each experiment, while, in the latter, infection was eliminated early in the time series, preserving a large proportion of live, uninfectious cells across the duration of the experiment. We assumed this pattern to be the result of immune-mediated epidemic extinction (Figure 1). Patterns from MOI = 0.001 were largely recapitulated at MOI = 0.0001, though at somewhat reduced total proportions (Figure 1—figure supplement 5). A theoretical model fit to in vitro data recapitulates expected immune phenotypes for bat cells We next developed a within-host model to fit to these data to elucidate the effects of induced and constitutive immunity on the dynamics of viral spread in host tissue (Figure 1). The compartmental within-host system mimicked our two-dimensional cell culture monolayer, with cells occupying five distinct infection states: susceptible (S), antiviral (A), exposed (E), infectious (I), and dead (D). We modeled exposed cells as infected but not yet infectious, capturing the ‘eclipse phase’ of viral integration into a host cell which precedes viral replication. Antiviral cells were immune to viral infection, in accordance with the 'antiviral state' induced from interferon stimulation of ISGs in tissues adjacent to infection (Stetson and Medzhitov, 2006). Because we aimed to translate available data into modeled processes, we did not explicitly model interferon dynamics but instead scaled the rate of cell progression from susceptible to antiviral (ρ) by the proportion of exposed cells (globally) in the system. In systems permitting constitutive immunity, a second rate of cellular acquisition of antiviral status (ε) additionally scaled with the global proportion of susceptible cells in the model. Compared with virus, IFN particles are small and highly diffusive, justifying this global signaling assumption at the limited spatial extent of a six-well plate and maintaining consistency with previous modeling approximations of IFN signaling in plaque assay (Howat et al., 2006). To best represent our empirical monolayer system, we expressed our state variables as proportions (PS, PA, PE, PI, and PD), under assumptions of frequency-dependent transmission in a well-mixed population (Keeling and Rohani, 2008), though note that the inclusion of PD (representing the proportion of dead space in the modeled tissue) had the functional effect of varying transmission with infectious cell density. This resulted in the following system of ordinary differential equations: (1) dPSdt=bPD(PS+ PA)−βPSPI−μPS−ρPEPS− εPS+cPA (2) dPAdt=ρPEPS+ εPS−cPA−μPA (3) dPEdt=βPSPI-σPE-μPE (4) dPIdt=σPE-αPI-μPI (5) dPDdt=μ(PS+PE+ PI+ PA)+αPI−bPD(PS+ PA) We defined 'induced immunity' as complete, modeling all cells as susceptible to viral invasion at disease-free equilibrium, with defenses induced subsequent to viral exposure through the term ρ. By contrast, we allowed the extent of constitutive immunity to vary across the parameter range of ε > 0, defining a 'constitutive' system as one containing any antiviral cells at disease-free equilibrium. In fitting this model to tissue culture data, we independently estimated both ρ and ε, as well as the cell-to-cell transmission rate, β, for each cell-virus combination. Since the extent to which constitutively-expressed IFN-α is constitutively translated into functional protein is not yet known for bat hosts (Zhou et al., 2016), this approach permitted our tissue culture data to drive modeling inference: even in PaKiT01 cell lines known to constitutively express IFN-α, the true constitutive extent of the system (i.e. the quantity of antiviral cells present at disease-free equilibrium) was allowed to vary through estimation of ε. For the purposes of model-fitting, we fixed the value of c, the return rate of antiviral cells to susceptible status, at 0. The small spatial scale and short time course (max 200 hours) of our experiments likely prohibited any return of antiviral cells to susceptible status in our empirical system; nonetheless, we retained the term c in analytical evaluations of our model because regression from antiviral to susceptible status is possible over long time periods in vitro and at the scale of a complete organism (Radke et al., 1974; Rasmussen and Farley, 1975; Samuel and Knutson, 1982). Before fitting to empirical time series, we undertook bifurcation analysis of our theoretical model and generated testable hypotheses on the basis of model outcomes. From our within-host model system (Equation 1-5), we derived the following expression for R0, the pathogen basic reproduction number (Supplementary file 2): (6) R0=βσ(b-μ)(c+μ)bσ+μα+μc+μ+ε Pathogens can invade a host tissue culture when R0>1. Rapid rates of constitutive antiviral acquisition (ε) will drive R0<1: tissue cultures with highly constitutive antiviral immunity will be therefore resistant to virus invasion from the outset. Since, by definition, induced immunity is stimulated following initial virus invasion, the rate of induced antiviral acquisition (ρ) is not incorporated into the equation for R0; while induced immune processes can control virus after initial invasion, they cannot prevent it from occurring to begin with. In cases of fully induced or absent immunity (ε=0), the R0 equation thus reduces to a form typical of the classic SEIR model: (7) R0=βσb-μbα+μσ+μ At equilibrium, the theoretical, mean field model demonstrates one of three infection states: endemic equilibrium, stable limit cycles, or no infection (Figure 2). Respectively, these states approximate the persistent infection, virus-induced epidemic extinction, and immune-mediated epidemic extinction phenotypes previously witnessed in tissue culture experiments (Figure 1). Theoretically, endemic equilibrium is maintained when new infections are generated at the same rate at which infections are lost, while limit cycles represent parameter space under which infectious and susceptible populations are locked in predictable oscillations. Endemic equilibria resulting from cellular regeneration (i.e. births) have been described in vivo for HIV (Coffin, 1995) and in vitro for herpesvirus plaque assays (Howat et al., 2006), but, because they so closely approach zero, true limit cycles likely only occur theoretically, instead yielding stochastic extinctions in empirical time series. Figure 2 Download asset Open asset Two parameter bifurcations of the mean field model, showing variation in the transmission rate, β, against variation in the pathogen-induced mortality rate, α, under diverse immune assumptions. Panel (A) depicts dynamics under variably constitutive immunity, ranging from absent (left: ε=0) to high (right: ε=.0025). In all panel (A) plots, the rate of induced immune antiviral acquisition (ρ) was fixed at 0.01. Panel (B) depicts dynamics under variably induced immunity, ranging from absent (left: ρ=0) to high (right: ρ=1). In all panel (B) plots, the rate of constitutive antiviral acquisition (ε)) was fixed at 0.0001 Branch point curves are represented as solid lines and Hopf curves as dashed lines. White space indicates endemic equilibrium (persistence), gray space indicates limit cycles, and black space indicates no infection (extinction). Other parameter values for equilibrium analysis were fixed at: b = .025, μ = .001, σ = 1/6, c = 0. Special points from bifurcations analyses are listed in Supplementary file 3. Bifurcation analysis of our mean field model revealed that regions of no infection (pathogen extinction) were bounded at lower threshold (Branch point) values for β, below which the pathogen was unable to invade. We found no upper threshold to invasion for β under any circumstances (i.e. β high enough to drive pathogen-induced extinction), but high β values resulted in Hopf bifurcations, which delineate regions of parameter space characterized by limit cycles. Since limit cycles so closely approach zero, high βs recovered in this range would likely produce virus-induced epidemic extinctions under experimental conditions. Under more robust representations of immunity, with higher values for either or both induced (ρ) and constitutive (ε) rates of antiviral acquisition, Hopf bifurcations occurred at increasingly higher values for β, meaning that persistent infections could establish at higher viral transmission rates (Figure 2). Consistent with our derivation for R0, we found that the Branch point threshold for viral invasion was independent of changes to the induced immune parameter (ρ) but saturated at high values of ε that characterize highly constitutive immunity (Figure 3). Figure 3 Download asset Open asset Two parameter bifurcations of the mean field model, showing variation in the transmission rate, β, against variation in: (A) the induced immunity rate of antiviral acquisition (ρ) and (B) the constitutive immunity rate of antiviral acquisition (ε). Panels show variation in the extent of immunity, from absent (left) to high (right). Branch point curves are represented as solid lines and Hopf curves as dashed lines. White space indicates endemic equilibrium (persistence), gray space indicates limit cycling, and black space indicates no infection (extinction). Other parameter values for equilibrium analysis were fixed at: b = .025, μ = .001, σ = 1/6, α = 1/6, c = 0. Special points from bifurcations analyses are listed in Supplementary file 3. We next fit our theoretical model by least squares to each cell line-virus combination, under absent, induced, and constitutive assumptions of immunity. In general, best fit models recapitulated expected outcomes based on the immune phenotype of the cell line in question, as described in the general literature (Table 1; Supplementary file 4). The absent immune model offered the most accurate approximation of IFN-deficient Vero cell time series, the induced immune model best recovered the RoNi/7.1 cell trials, and, in most cases, the constitutive immune model most closely recaptured infection dynamics across constitutively IFN-α-expressing PaKiT01 cell lines (Figure 1, Figure 1—figure supplements 4–5, Supplementary file 4). Ironically, the induced immune model offered a slightly better fit than the constitutive to rVSV-MARV infections on the PaKiT01 cell line (the one cell line-virus combination for which we know a constitutively antiviral cell-receptor incompatibility to be at play). Because constitutive immune assumptions can prohibit pathogen invasion (R0<1), model fits to this time series under constitutive assumptions were handicapped by overestimations of ε, which prohibited pathogen invasion. Only by incorporating an exceedingly rapid rate of induced antiviral acquisition could the model guarantee that initial infection would be permitted and then rapidly controlled. Table 1 Optimized parameters from best fit deterministic model and spatial approximation at MOI = 0.001 Cell lineVirusImmune assumptionAIC reduction from next-best modelAntiviral rateε [lci – uci] *ρ [lci – uci] *β [lci – uci] *Mean field R0Spatial βVerorVSV-GAbsent200 [0–0]0 [0–0]2.44 [1.52–3.36]8.7324.418 rVSV-EBOVAbsent200 [0–0]0 [0–0]1.5 [1.06–1.94]5.4214.996 rVSV-MARVAbsent200 [0–0]0 [0–0]0.975 [0.558–1.39]3.459.752RoNi/7.1rVSV-GInduced27.03 × 10−50 [0–0]0.089 [0–0.432]2.47 [1.49–3.45]10.9124.705 rVSV-EBOVInduced2.012.87 × 10−50 [0–0]0.0363 [0–0.343]0.685 [0.451–0.919]3.046.849 rVSV-MARVInduced21.40 × 10−50 [0–0]0.0177 [0–0.257]1.23 [0.917–1.55]5.4812.324PaKiT01rVSV-GConstitutive29.9.002090.00602 [0–0.019]8.26 × 10−8 [0–4.75 × 10−7]3.45 [1.07–5.84]6.2034.516 rVSV-EBOVConstitutive27.9.004990.0478 [0–0.0958]4.46 × 10−8 [0–4.37 × 10−7]34.5 [28.7–40.2]18.82344.821 rVSV-MARVInduced2.006870 [0–0]13.1 [0–37.9]3.25 [0–41.3]8.8332.452 Improvement in AIC from next best model for same cell line-virus-MOI combination. All δ-AIC are reported in Supplementary file 4. *lci = lower and uci = upper 95% confidence interval. No confidence interval is shown for spatial β which was fixed at 10 times the estimated mean for the mean field model fits when paired with equivalent values of ε and ρ. All other parameters were fixed at: b = 0.025 (mean field), 0.15 (spatial); α = 1/6; c = 0; μ = 1/121 (Vero), 1/191 (RoNi/7.1), and 1/84 (PaKiT01). Robust immunity is linked to rapid within-host virus transmission rates in fitted models In fitting our theoretical model to in vitro data, we estimated the within-host virus transmission rate (β) and the rate(s) of cellular acquisition to antiviral status (ρ or ρ + ε) (Table 1; Supplementary file 4). Under absent immune assumptions, ρ and ε were fixed at 0 while β was estimated; under induced immune assumptions, ε was fixed at 0 while ρ and β were estimated; and under constitutive immune assumptions, all three parameters (ρ, ε, and β) were simultaneously estimated for each cell-virus combination. Best fit parameter estimates for MOI=0.001 data are visualized in conjunction with β – ρ and β – ε bifurcations in Figure 4; all general patterns were recapitulated at lower values for β on MOI=0.0001 trials (Figure 4—figure supplement 1). As anticipated, the immune absent model (a simple target cell model) offered the best fit to IFN-deficient Vero cell infections (Figure 4; Table 1; Supplementary file 4). Among Vero cell trials, infections with rVSV-G produced the highest β estimates, followed by infections with rVSV-EBOV and rVSV-MARV. Best fit parameter estimates on Vero cell lines localized in the region of parameter space corresponding to theoretical limit cycles, consistent with observed virus-induced epidemic extinctions in stochastic tissue cultures. Figure 4 with 1 supplement see all Download asset Open asset Best fit parameter estimates for β and ρ or ε from mean-field model fits to MOI=0.001 time series data, atop (A,B) β – ρ and (C) β – ε bifurcation. Fits and bifurcations are grouped by immune phenotype: (A) absent; (B) induced; (C) constitutive immunity, with cell lines differentiated by shape (Vero=circles; RoNi/7.1 = triangles; PaKiT01=squares) and viral infections by color (rVSV-G = green, rVSV-EBOV = magenta, rVSV-MARV = blue). Note that y-axis values are ten-fold higher in panel (C). Branch point curves (solid lines) and Hopf curves (dashed lines) are reproduced from Figure 3. White space indicates endemic equilibrium (pathogen persistence), gray space indicates limit cycling (virus-induced epidemic extinction), and black space indicates no infection (immune-mediated pathogen extinction). In panel (A) and (B), ε is fixed at 0; in panel (C), ρ is fixed at 5x10−8 for bifurcation curves and estimated at 4x10−8 and 8x10−8 for rVSV-EBOV and rVSV-G parameter points, respectively. Other parameter values were fixed at: b = .025, μ = 0.001, σ = 1/6, α = 1/6, and c = 0 across all panels. Raw fitted values and corresponding 95% confidence intervals for β, ρ, and ε, background parameter values, and AIC recovered from model fit, are reported in Supplementary file 4. Parameter fits at MOI=0.0001 are visualized in Figure 4—figure supplement 1. In contrast to Vero cells, the induced immunity model offered the best fit to all RoNi/7.1 data, consistent with reported patterns in the literature and our own validation by qPCR (Table 1; Figure 1—figure supplement 6; Arnold et al., 2018; Kuzmin et al., 2017; Biesold et al., 2011; Pavlovich et al., 2018). As in Vero cell trials, we estimated highest β values for rVSV-G infections on RoNi/7.1 cell lines but here recovered higher β estimates for rVSV-MARV than for rVSV-EBOV. This reversal was balanced by a higher estimated rate of acquisition to antiviral status (ρ) for rVSV-EBOV versus rVSV-MARV. In general, we observed that more rapid rates of antiviral acquisition (either induced, ρ, constitutive, ε, or both) correlated with higher transmission rates (β). When offset by ρ, β values estimated for RoNi/7.1 infections maintained the same amplitude as those estimated for immune-absent Vero cell lines but caused gentler epidemics and reduced cellular mortality (Figure 1). RoNi/7.1 parameter estimates localized in the region corresponding to endemic equilibrium for the deterministic, theoretical model (Figure 4), yielding less acute epidemics which nonet" @default.
- W3011981165 created "2020-03-23" @default.
- W3011981165 creator A5007968840 @default.
- W3011981165 creator A5010580342 @default.
- W3011981165 creator A5011461272 @default.
- W3011981165 creator A5018222452 @default.
- W3011981165 creator A5022633993 @default.
- W3011981165 creator A5026340220 @default.
- W3011981165 creator A5034347595 @default.
- W3011981165 creator A5035603577 @default.
- W3011981165 creator A5041846756 @default.
- W3011981165 creator A5049518482 @default.
- W3011981165 creator A5089260834 @default.
- W3011981165 date "2020-01-04" @default.
- W3011981165 modified "2023-10-15" @default.
- W3011981165 title "Author response: Accelerated viral dynamics in bat cell lines, with implications for zoonotic emergence" @default.
- W3011981165 doi "https://doi.org/10.7554/elife.48401.sa2" @default.
- W3011981165 hasPublicationYear "2020" @default.
- W3011981165 type Work @default.
- W3011981165 sameAs 3011981165 @default.
- W3011981165 citedByCount "4" @default.
- W3011981165 countsByYear W30119811652021 @default.
- W3011981165 countsByYear W30119811652023 @default.
- W3011981165 crossrefType "peer-review" @default.
- W3011981165 hasAuthorship W3011981165A5007968840 @default.
- W3011981165 hasAuthorship W3011981165A5010580342 @default.
- W3011981165 hasAuthorship W3011981165A5011461272 @default.
- W3011981165 hasAuthorship W3011981165A5018222452 @default.
- W3011981165 hasAuthorship W3011981165A5022633993 @default.
- W3011981165 hasAuthorship W3011981165A5026340220 @default.
- W3011981165 hasAuthorship W3011981165A5034347595 @default.
- W3011981165 hasAuthorship W3011981165A5035603577 @default.
- W3011981165 hasAuthorship W3011981165A5041846756 @default.
- W3011981165 hasAuthorship W3011981165A5049518482 @default.
- W3011981165 hasAuthorship W3011981165A5089260834 @default.
- W3011981165 hasBestOaLocation W30119811651 @default.
- W3011981165 hasConcept C121332964 @default.
- W3011981165 hasConcept C145912823 @default.
- W3011981165 hasConcept C159047783 @default.
- W3011981165 hasConcept C24890656 @default.
- W3011981165 hasConcept C70721500 @default.
- W3011981165 hasConcept C78458016 @default.
- W3011981165 hasConcept C86803240 @default.
- W3011981165 hasConceptScore W3011981165C121332964 @default.
- W3011981165 hasConceptScore W3011981165C145912823 @default.
- W3011981165 hasConceptScore W3011981165C159047783 @default.
- W3011981165 hasConceptScore W3011981165C24890656 @default.
- W3011981165 hasConceptScore W3011981165C70721500 @default.
- W3011981165 hasConceptScore W3011981165C78458016 @default.
- W3011981165 hasConceptScore W3011981165C86803240 @default.
- W3011981165 hasLocation W30119811651 @default.
- W3011981165 hasOpenAccess W3011981165 @default.
- W3011981165 hasPrimaryLocation W30119811651 @default.
- W3011981165 hasRelatedWork W1641042124 @default.
- W3011981165 hasRelatedWork W1990804418 @default.
- W3011981165 hasRelatedWork W1993764875 @default.
- W3011981165 hasRelatedWork W2013243191 @default.
- W3011981165 hasRelatedWork W2051339581 @default.
- W3011981165 hasRelatedWork W2061542922 @default.
- W3011981165 hasRelatedWork W2082860237 @default.
- W3011981165 hasRelatedWork W2117258802 @default.
- W3011981165 hasRelatedWork W2130076355 @default.
- W3011981165 hasRelatedWork W2151865869 @default.
- W3011981165 isParatext "false" @default.
- W3011981165 isRetracted "false" @default.
- W3011981165 magId "3011981165" @default.
- W3011981165 workType "peer-review" @default.